Trial Profile
Safety and Immunogenicity of Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years: a Four-arm, Double-blind, Non-inferiority Trial
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs NVX CoV 2373 (Primary) ; Pneumococcal 20-valent conjugate vaccine (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- 05 Jan 2024 Nuvaxovid (NVXCoV 2373) is added to treatments as a test drug.
- 20 Mar 2023 New trial record